IRB approval on track as scheduledNext step is obtaining all regulatory approvals, followed by site initiation visitVELDONA significantly increases unstimulated...
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with evidence of...
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder...
Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose...
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a...
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer...
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunitiesSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024...
Institutional Investment of £600,000Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials LONDON, UNITED KINGDOM / ACCESSWIRE / November 11,...
ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe...
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical...
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS...
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected...
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort...
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with...
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish...
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for...
Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T...
SINGAPORE, Nov. 8, 2024 /PRNewswire/ -- HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present...
SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare...
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose...